Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bathroom breakthrough: new wash may stop UTIs in older women

NCT ID NCT06598514

Prevention Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a chlorhexidine rinse after bowel movements can reduce urinary tract infections (UTIs) in post-menopausal women who already use vaginal estrogen and have frequent UTIs. About 136 women aged 55-89 will be randomly assigned to use either the chlorhexidine rinse or a plain water rinse. The main goal is to see if the chlorhexidine group has fewer UTIs over 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 89 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Post-menopausal female between age 55 and 89 * No post-menopausal bleeding * Diagnosis of recurrent urinary tract infection (UTI) in the electronic health record or as two culture proven UTIs in 6 months or three culture proven UTIs in 12 months * At least one UTI in the 6 months prior to entering the study * Asymptomatic for UTI symptoms at the time of enrollment. * On vaginal estrogen therapy for at least 6 weeks prior to enrollment * Ready access to email and internet Exclusion Criteria: * Recent prophylactic antibiotic use (washout period of 4 weeks) * Neurogenic bladder * Diagnosis of urinary retention * Uncorrected Stage III-IV prolapse * Indwelling catheter or need for intermittent self-catheterization * History of complicated UTIs * History of interstitial cystitis or bladder pain syndrome * History of fecal incontinence/accidental bowel leakage * Greater than 14 bowel movements per week * Non-English speaking * Allergy to chlorhexidine gluconate * Inability to utilize vaginal estrogen therapy * Recent urogynecological or urologic surgery (\<12 weeks)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent urinary tract infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary tract infection urinary tract infections, recurrent, susceptibility to

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent urinary tract infection Urinary tract infections

Contacts and locations

Locations

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.